Eque-cel for immune-mediated necrotizing myopathy that hasn't improved
Treatments studied
This trial is testing a new CAR-T cell treatment (Eque-cel) for people with a rare muscle disease called immune-mediated necrotizing myopathy that hasn't improved with standard treatments. The treatment aims to stop the immune system from attacking the muscles.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 or older
- Diagnosed with immune-mediated necrotizing myopathy (IMNM)
- Test positive for anti-SRP or anti-HMGCR antibodies
- Tried standard treatment and the disease is still active
- Adequate organ function (heart, lungs, kidneys, liver)
- Willing to use effective contraception for up to 1 year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new CAR-T cell therapy called Eque-cel for people with multiple myeloma that no longer responds to lenalidomide. It aims to see if this treatment can help control the disease after 1-2 prior therapies.
This trial is studying a new treatment called equecabtagene autoleucel for people whose multiple myeloma has come back or stopped responding to other treatments. It aims to see how well this therapy works in real-world medical settings.
This trial tests a universal CAR-T cell treatment for people with autoimmune diseases of the nervous system that haven't responded to standard therapies. It aims to see if this therapy can help control diseases like neuromyelitis optica, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multiple sclerosis.
This trial tests a new treatment called RD06-04, which uses specially modified immune cells (CAR-T cells) to target and attack cells causing two autoimmune diseases: inflammatory myopathies (IIM) and ANCA-associated vasculitis (AAV). It is an early study to see if this therapy is safe and effective.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a treatment called CNCT19, a type of CAR-T cell therapy, for people with certain autoimmune diseases like neuromyelitis optica, myasthenia gravis, or multiple sclerosis that have come back or not responded to other treatments. It aims to see if targeting a specific immune cell (CD19) can help control the disease.
Hear when a new Refractory Immune-mediated Necrotizing Myopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.